Rates of BRCA1/2 mutation testing among young survivors of breast cancer

Breast Cancer Research and Treatment

Volumn 155, Issue 1, 2016, Pages 165-173

  Kehl, Kenneth L ^a   Shen, Chan ^a   Litton, Jennifer K ^a   Arun, Banu ^a   Giordano, Sharon H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

BRCA1; BRCA2; Breast cancer genetics; Health services research

Indexed keywords

ADULT; ARTICLE; BIOGEOGRAPHIC REGION; BREAST CANCER; CANCER INCIDENCE; CANCER SURVIVOR; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; PRIORITY JOURNAL; TIME TO TREATMENT; TREND STUDY; TUMOR SUPPRESSOR GENE; AGE; BREAST NEOPLASMS; GENETICS; KAPLAN MEIER METHOD; MUTATION; PROPORTIONAL HAZARDS MODEL; SURVIVOR; YOUNG ADULT;

ADULT; AGE FACTORS; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC TESTING; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MUTATION; PROPORTIONAL HAZARDS MODELS; SURVIVORS; YOUNG ADULT;

EID: 84953350951     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3658-y     Document Type: Article

References (36)

1. Foulkes WD (2008) Inherited susceptibility to common cancers. N Engl J Med 359:2143–2153. doi:10.1056/NEJMra0802968
2. Pharoah PDP, Antoniou A, Bobrow M et al (2002) Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 31:33–36. doi:10.1038/ng853
3. Antoniou A, Pharoah PDP, Narod S et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117–1130. doi:10.1086/375033
4. National comprehensive cancer network. Genetic/familial high-risk screening: breast. Version 1.2001
5. National comprehensive cancer network. Genetic/familial high-risk assessment: breast and ovarian. Version 1.2005
6. National comprehensive cancer network. Genetic/familial high-risk assessment: breast and ovarian. Version 1.2009
7. National comprehensive cancer network. Genetic/familial high-risk assessment: breast and ovarian. Version 2.2014
8. Levy DE, Byfield SD, Comstock CB et al (2011) Underutilization of BRCA1/2 testing to guide breast cancer treatment: black and Hispanic women particularly at risk. Genet Med 13:349–355. doi:10.1097/GIM.0b013e3182091ba4
9. American Cancer Society (2015) Breast cancer key statistics. http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-key-statistics. Accessed 29 Nov 2015
10. American Cancer Society (2015) American Cancer Society estimated new cases for the four major cancers by sex and age group. http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044511.pdf. Accessed 29 Nov 2015
11. Easton DF, Pharoah PDP, Antoniou AC et al (2015) Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med 372:2243–2257. doi:10.1056/NEJMsr1501341
12. Phimister EG (2015) Curating the way to better determinants of genetic risk. N Engl J Med 372:2227–2228. doi:10.1056/NEJMe1506276
13. Tung N, Battelli C, Allen B et al (2015) Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer 121:25–33. doi:10.1002/cncr.29010
14. Desmond A, Kurian AW, Gabree M et al (2015) Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment. JAMA Oncol 1:943–951. doi:10.1001/jamaoncol.2015.2690
15. Snyder CF, Frick KD, Peairs KS et al (2009) Comparing care for breast cancer survivors to non-cancer controls: a five-year longitudinal study. J Gen Intern Med 24:469–474. doi:10.1007/s11606-009-0903-2
16. Kwon JS, Gutierrez-Barrera AM, Young D et al (2010) Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol 28:4214–4220. doi:10.1200/JCO.2010.28.0719
17. Hansen L, Chang S (2011) White paper: health research data for the real world: the Thomson Reuters marketscan databases. Thomson Reuters, New York, p 32
18. Barcenas CH, Niu J, Zhang N et al (2014) Risk of hospitalization according to chemotherapy regimen in early-stage breast cancer. J Clin Oncol 32:2010–2017
19. Nattinger AB, Laud PW, Bajorunaite R et al (2004) An algorithm for the use of Medicare claims data to identify women with incident breast cancer. Health Serv Res 39:1733–1749. doi:10.1111/j.1475-6773.2004.00315.x
20. Giordano SH, Lin YL, Kuo YF et al (2012) Decline in the use of anthracyclines for breast cancer. J Clin Oncol 30:2232–2239. doi:10.1200/JCO.2011.40.1273
21. Gold HT, Do HT (2007) Evaluation of three algorithms to identify incident breast cancer in Medicare claims data. Health Serv Res 42:2056–2069. doi:10.1111/j.1475-6773.2007.00705.x
22. Centers for Medicare & Medicaid Services (CMS). CMS manual system, pub 100-04 Medicare claims processing, transmittal 2639, change request 8162. Effective date January 1, 2013. https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/Downloads/R2639CP.pdf. Accessed 15 Feb 2015
23. Centers for Medicare & Medicaid Services (CMS). CMS manual system, pub 100-04, Medicare claims processing. Transmittal 2423, change request 7751. Effective date: April 1, 2012. http://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/downloads/R2423CP.pdf. Accessed 15 Feb 2015
24. Hall WJ, Wellner JA (1980) Confidence bands for a survival curve from censored data. Biometrika 67:133–143
25. Anders CK, Johnson R, Litton J et al (2009) Breast cancer before age 40 years. Semin Oncol 36:237–249. doi:10.1053/j.seminoncol.2009.03.001
26. Jóhannsson OT, Ranstam J, Borg A, Olsson H (1998) Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol 16:397–404
27. Brekelmans CTM, Seynaeve C, Menke-Pluymers M et al (2006) Survival and prognostic factors in BRCA1-associated breast cancer. Ann Oncol 17:391–400. doi:10.1093/annonc/mdj095
28. Verhoog LC, Brekelmans CTM, Seynaeve C et al (1998) Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 351:316–321. doi:10.1016/S0140-6736(97)07065-7
29. Rennert G, Bisland-Naggan S, Barnett-Griness O et al (2007) Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357:115–123. doi:10.1056/NEJMoa070608
30. El-Tamer M, Russo D, Troxel A et al (2004) Survival and recurrence after breast cancer in BRCA1/2 mutation carriers. Ann Surg Oncol 11:157–164. doi:10.1245/ASO.2004.05.018
31. Bordeleau L, Panchal S, Goodwin P (2010) Prognosis of BRCA-associated breast cancer: a summary of evidence. Breast Cancer Res Treat 119:13–24. doi:10.1007/s10549-009-0566-z
32. Bayraktar S, Gutierrez-Barrera AM, Liu D et al (2011) Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat 130:145–153. doi:10.1007/s10549-011-1711-z
33. Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975–2011, National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/csr/1975_2011/. Based on November 2013 SEER data submission, posted to the SEER web site, April 2014
34. McCabe MS, Bhatia S, Oeffinger KC et al (2013) American society of clinical oncology statement: achieving high-quality cancer survivorship care. J Clin Oncol 31:631–640. doi:10.1200/JCO.2012.46.6854
35. Gnerlich JL, Deshpande AD, Jeffe DB et al (2011) Poorer survival outcomes for male breast cancer compared with female breast cancer may be attributable to in-stage migration. Ann Surg Oncol 18:1837–1844. doi:10.1245/s10434-010-1468-3
36. Gnerlich J, Jeffe DB, Deshpande AD et al (2007) Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: analysis of the 1988-2003 SEER data. Ann Surg Oncol 14:2187–2194. doi:10.1245/s10434-007-9438-0